<DOC>
	<DOC>NCT01840280</DOC>
	<brief_summary>The main purpose of this observational study with Irinotecan onkovis is to determine the number of treatment cycles and the quantity of Irinotecan onkovis needed for this purpose under the special circumstances of ambulant chemotherapy. Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This includes provision of appropriate packaging sizes to decrease the excess quantity to be discarded, and thus also follows this objective. Secondary objective is the assessment of the side effects of Irinotecan onkovis. To this end, data regarding co-medication and adverse events are also collected.</brief_summary>
	<brief_title>A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Indication for Irinotecan according to the SmPC and treating physician according to the Irinotecan SmPC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>carcinoma</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>ambulant chemotherapy</keyword>
	<keyword>treatment cycles</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Irinotecan onkovis</keyword>
	<keyword>Quantity of Irinotecan</keyword>
	<keyword>Packaging Sizes</keyword>
</DOC>